Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

60.06
Delayed Data
As of Dec 07
 -0.22 / -0.36%
Today’s Change
47.97
Today|||52-Week Range
65.46
+13.71%
Year-to-Date
MRK Regular Dividend: MRK will begin trading ex-dividend on 12/13/16 with a $0.47 dividend payable to shareholders of record as of 12/15/16.
Top Research Reports for Cisco, Merck & MasterCard
Dec 07 / Zacks.com - Paid Partner Content
Why Bristol-Myers Squibb Co. Stock Surged in November
Dec 03 / MotleyFool.com - Paid Partner Content
Why AstraZeneca plc Stock Slumped in November
Dec 07 / MotleyFool.com - Paid Partner Content
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma
Dec 02 / Zacks.com - Paid Partner Content
Lilly: Jardiance Label to Add Cardiovascular Indication
Dec 06 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytr...
Dec 02 / Zacks.com - Paid Partner Content
Intermediate Trade: Merck
Dec 06 / TheStreet.com - Paid Partner Content
Alexandria Real Estate, Merck Ink Long-Term Pharma Lease
Dec 01 / Zacks.com - Paid Partner Content
Kite Pharma Begins Filing for KTE-C19, Presents Data at ASH
Dec 05 / Zacks.com - Paid Partner Content
5 Top Performing S&P 500 Stocks of November
Dec 01 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close60.28
Today’s open59.70
Day’s range58.62 - 60.06
Volume14,049,574
Average volume (3 months)10,789,467
Market cap$166.2B
Dividend yield3.13%
Data as of 12/07/2016

Growth & Valuation

Earnings growth (last year)-61.67%
Earnings growth (this year)+5.11%
Earnings growth (next 5 years)+6.00%
Revenue growth (last year)-7.92%
P/E ratio30.6
Price/Sales3.87
Price/Book3.75

Competitors

 Today’s
change
Today’s
% change
NVSNovartis-0.34-0.49%
PFEPfizer-0.37-1.17%
SNYSanofi-0.14-0.34%
ABBVAbbVie-1.63-2.65%
Data as of 12/07/2016

Financials

Next reporting dateFebruary 8, 2017
EPS forecast (this quarter)$0.89
Annual revenue (last year)$38.8B
Annual profit (last year)$4.4B
Net profit margin11.46%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
Chairman, President &
Chief Executive Officer
Kenneth C. Frazier
Chief Financial Officer &
Executive Vice President
Robert M. Davis
Corporate headquarters
Kenilworth, New Jersey

Forecasts


Search for Jobs